

000FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

REV. 2/01T

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

CUSTOMER NO. **22,852**
ATTORNEY'S DOCKET NUMBER

03715.0148

U.S. APPLICATION NO.
(If known, see 37CFR1.5)

10/542495

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/FR2004/000086

January 16, 2004

January 17, 2003

TITLE OF INVENTION

**USE OF 3-METHOXY-PREGNENOLONE IN THE PRODUCTION OF A MEDICAMENT FOR TREATING
NEURODEGENERATIVE DISEASES**

APPLICANT(S) FOR DO/EO/US: 1) Etienne-Emile BAULIEU; 2) Esther FELLOUS; 3) Paul ROBEL

Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed with the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154 (d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)), including 12 claims.

Items 11 to 20 below concern document(s) or information included:

11. ☐ Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A Substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154 (d)(4).
19. ☐ A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20. ☒ Other items or information:
 - a. ☒ Copy of cover page of International Publication No. **2004/067010 A1**
 - b. ☐ Copy of Notification of Missing Requirements.
 - c. ☒ Verification of Translation (1 page)
 - d. ☒ Request for Substitution of Replacement Sheets

1980-000000000 1 5 JUL 2005

U.S. APPLICATION NO. (if known, see 37CFR 1.5) <div style="font-size: 2em; font-weight: bold; margin-top: 5px;">10/542495</div>		INTERNATIONAL APPLICATION NO. <div style="font-weight: bold; margin-top: 5px;">PCT/FR2004/000086</div>		ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold; margin-top: 5px;">03715.0148</div>	
21. <input checked="" type="checkbox"/> The following fees are submitted: <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</div> <div>\$300.00</div> </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div>National Stage Search Fee.....</div> <div>\$500.00</div> </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div>National Stage Examination Fee.....</div> <div>\$200.00</div> </div> <div style="text-align: right; margin-top: 10px;"> ENTER APPROPRIATE BASIC FEE AMOUNT = </div>				Applicant Use \$ \$ \$	Office Use Only
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of additional 50 or fraction thereof (rounded up to a whole number)	Rate		
32			x 250.00	\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <div style="display: flex; justify-content: flex-end; margin-top: 5px;"> <input type="checkbox"/> 20 <input type="checkbox"/> 30 </div>				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	14	- 20 =	x \$50.00	\$	
Independent Claims	5	-3 =	x \$200.00	\$ 400.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+\$360.00	\$ 360.00	
TOTAL OF THE ABOVE CALCULATIONS =				\$1760.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				\$-880.00	
SUBTOTAL =				\$ 880.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest priority date (37 CFR 1.492(f)). <div style="display: flex; justify-content: flex-end; margin-top: 5px;"> <input type="checkbox"/> 20 <input type="checkbox"/> 30 </div>				\$	
TOTAL NATIONAL FEE =				\$ 880.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$	
TOTAL FEES ENCLOSED =				\$ 880.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>880.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0916</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 901 New York Avenue, NW Washington, D.C. 20001-4413 KJM/EFC/FPD/blc DATED: July 15, 2005					
			 SIGNATURE Ernest F. Chapman, Reg. No. 25,961 NAME/REGISTRATION NO.		

10/542495

JC20 Rec'd PCT/PTO 1 5 JUL 2005

VERIFICATION OF TRANSLATION

I, Harold William VADNEY III

of: P.O. Box 407 -- 18 New Street - New Baltimore, New York 12124-0407 -United
States of America

declare as follows :

1. That I am well acquainted with both the English and French languages, and
2. That the attached document is a true and correct translation made by me to the best of my knowledge and belief, of:

the patent application entitled:

USE OF 3-METHOXY-PREGNENOLONE IN THE PRODUCTION OF A
MEDICAMENT FOR TREATING NEURODEGENERATIVE DISEASES

Date of publication: 12.08.2004
Publication N° WO 2004/067010 A1

Date: 29 June 2005

Signature of Translator



Harold William Vadney III